MONTREAL, Nov. 2, 2006 (PRIMEZONE) -- Viropro Inc. (OTCBB:VPRO) ("Viropro") is pleased to announce the appointment of Gino Di Iorio, C.A. as Chief Financial Officer. "Since he joined Viropro in May 2006 as Director of Finance and Administration, Mr. Di Iorio has contributed to Viropro with strong experience in the finance sector through strategic financial planning and entrepreneurial organizational management," said Dr. Jean-Marie Dupuy, President and CEO of Viropro.
In a career spanning 14 years, Mr. Di Iorio has acquired operational management capabilities, and valuable experience in the high-tech, advertising and construction industries. He has held Finance Director positions for Sitel Canada and Draft Quebec (IPG subsidiary) both traded on the New York Stock Exchange.
"Through this appointment, Viropro Inc. is even better positioned to optimize the value of its assets and those of its shareholders in the short and long-term period," added Dr. Jean-Marie Dupuy.
About Viropro Inc.
Viropro Inc. conducts operations mainly through its subsidiary Viropro International Inc., whose head office is located in Montreal, Canada. Viropro is a rapidly expanding biopharmaceutical company specializing in the transfer of its technologies for industrial production of biogeneric therapeutic proteins, excluding therapeutic vaccines, for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The company's principal objective is to bring about the transfer of technology to pharmaceutical companies in emerging markets with unmet medical needs such as in South America, Asia and Africa. To expand its range of expertise in biopharmaceuticals excluding therapeutic vaccines, Viropro has concluded strategic alliances with various scientific and business partners renowned in national and international spheres. Viropro's business model rests on a strategy aimed at generating recurrent short and long-term revenues, all while maximizing the value of assets and profits of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.